-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

653A.O3.6 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation; Novel Approaches for Relapsed/Refractory Myeloma and Amyloidosis

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
multiple myeloma, Adult, antibodies, Biological, Diseases, Non-Biological, Therapies, Combinations, Plasma Cell Disorders, immunotherapy, Lymphoid Malignancies, Study Population, Clinically relevant
Monday, December 7, 2020: 1:30 PM-3:00 PM
Moderators:
Elena Zamagni, MD, Bologna University School of Medicine and Amrita Krishnan, MD, City of Hope Medical Center
Disclosures:
Zamagni: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Speakers Bureau; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Speakers Bureau; Takeda: Honoraria, Other: Travel, Accommodations, Expenses, Speakers Bureau; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Speakers Bureau; Celgene Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.
1:30 PM

Niels W.C.J. Van De Donk1, Rakesh Popat2*, Jeremy Larsen3, Monique C. Minnema4, Sundar Jagannath, MD5*, Albert Oriol6*, Jeffrey Zonder7, Paul G. Richardson, MD8, Paula Rodriguez-Otero, MD, PhD9*, Ashraf Z. Badros, MD10, Edward Stadtmauer11*, Sara Bringhen, MD12, Erica Campagnaro, MD13*, David S. Siegel, MD14, Barbara Gamberi15*, Mercedes Gironella Mesa16*, Pieter Sonneveld, MD, PhD17, Tuong Vi Nguyen18*, Antonia Di Micco19*, April Sorrell18*, Min Chen18*, Michael Amatangelo18*, Elisabeth Kueenburg19* and Sagar Lonial, MD20

1Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands
2NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom
3Mayo Clinic, Scottsdale, AZ
4Department of Hematology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
5The Mount Sinai Hospital, New York, NY
6Institut Josep Carreras and Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain
7Karmanos Cancer Institute, Detroit, MI
8Dana-Farber Cancer Institute, Boston, MA
9Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain
10The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, MD
11University of Pennsylvania, Philadelphia, PA
12Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
13Michigan Medicine Hematology Clinic, University of Michigan Rogel Cancer Center, Ann Arbor, MI
14Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
15Hematology Unit, AUSL-IRCSS, Reggio Emilia, Italy
16University Hospital Vall d'Hebron, Barcelona, Spain
17Erasmus Medical Center Rotterdam, Rotterdam, Netherlands
18Bristol Myers Squibb, Princeton, NJ
19Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
20Winship Cancer Institute of Emory University, Atlanta, GA

1:45 PM

Suzanne Trudel, MD, MSC, FRCPC1, Arleigh McCurdy, MD, BSc2, Heather J Sutherland, MD, PhD3,4, Martha L Louzada, MD, MSc5, Christopher P. Venner, MD6, Darrell J White, MD7, Rami Kotb, MD8*, Hira S Mian, MD9, Fernando Camacho, PhD10*, Molei Fu10*, Engin Gul, BS, MBA11*, Donna E. Reece, MD10 and Ibraheem Othman, MD, MSc, PhD12

1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
2Department of Medicine, Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada
3Leukemia/BMT Program of BC, BC Cancer, Vancouver, BC, Canada
4Vancouver General Hospital, Vancouver, BC, Canada
5London Health Sciences Centre, London, ON, Canada
6Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
7Nova Scotia Health Authority, Halifax, NS, Canada
8Cancer Care Manitoba, Winnipeg, MB, Canada
9Department of Oncology, McMaster University, Hamilton, ON, Canada
10Canadian Myeloma Research Group (formerly MCRN), Vaughan, ON, Canada
11Canadian Myeloma Research Group, Toronto, ON, Canada
12Allan Blair Cancer Centre, Regina, SK, CAN

2:00 PM

Christine I Chen, MD1, Nizar Bahlis, MD2, Cristina Gasparetto, MD3, Sascha A Tuchman, MD4, Brea Lipe, MD5, Muhamed Baljevic, MD6, Rami Kotb, MD7*, Heather J Sutherland, MD, PhD8, William I Bensinger, MD9*, Michael Sebag, MD, PhD10,11, Richard LeBlanc, MD, FRCPC12, Christopher P. Venner, MD13, Gary J. Schiller, MD14, Suzanne Lentzsch, MD, PhD15, Natalie S. Callander, MD16, Adriana C Rossi, MD, MSc17*, Noa Biran, MD18, Heidi Sheehan19*, Dane Van Domelen, PhD19*, Kai Kazuharu, MD, PhD19*, Hongwei Wang, MD, PhD19*, Jatin Shah, MD20, Sharon Shacham, PhD, MBA20*, Michael G Kauffman, MD, PhD20 and Darrell J White, MD21

1Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
2Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
3Department of Medicine, Duke University Cancer Institute, Durham, NC
4University of North Carolina, Chapel Hill, NC
5University of Rochester Medical Center, Rochester, NY
6Division of Oncology and Hematology, University of Nebraska Medical Center- Fred & Pamela Buffett Cancer Center, Omaha, NE
7Cancer Care Manitoba, Winnipeg, MB, Canada
8Vancouver General Hospital, Vancouver, BC, Canada
9Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
10Division of Hematology, McGill University Health Centre, Montreal, QC, Canada
11Royal Victoria Hospital, Montreal, QC, Canada
12Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada
13Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
14David Geffen School of Medicine at University of California, Los Angeles, CA
15Colombia University, New York
16Carbone Cancer Center, University of Wisconsin, Madison, WI
17Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY
18John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
19Karyopharm Therapeutics Inc., Newton, MA
20Karyopharm Therapeutics, Newton, MA
21Dalhousie University and QEII Health Sciences Centre, Halifax, NS, Canada

2:15 PM

Yael C Cohen, MD1,2*, Mor Zada, MSc3*, Shuang-Yin Wang4*, Chamutal Bornstein, PhD5*, Eyal David6*, Adi Moshe, PhD7*, Baoguo Li, PhD5*, Shir Shlomi7*, Moshe Gatt, MD8, Noa Lavi, MD9*, Chezi Ganzel, MD10*, Efrat Lutwak, MD11*, Ory Rouvio, MD12*, Iuliana Vaxman, MD, BA13*, Oren Pasvolsky, MD14*, Mouna Ballan15*, Tamar Tadmor, MD16*, Anatoly Nemets17*, Osnat Jarchowcky Dolberg18*, Yevgeny Chober19*, Olga Shvetz, MD20*, Merav Leiba21*, Ofer Shpilberg, MD, MPH22*, Nagib Deli23*, Irit Avivi, MD2,24*, Assaf Weiner, PhD3* and Ido Amit, PhD3*

1Hematology Department, self, tel aviv, Israel
2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3Weizmann Institute of Science, Rehovot, Israel
4Wetzmann Institute of Science, Rehovot, Israel
5Immunology, Weizmann Institute, Rehovot, Israel
6Weizmann INstitute, Rehovot, Israel
7Weizmann Institute, Rehovot, Israel
8Department of Hematology, Hadassah-Hebrew University Medical Center-, Jerusalem, Israel
9Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel
10Hematology, Shaare Zedek Medical Center, Jerusalem, Israel
11Department of Hematology, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel
12Soroka Medical center, Be'er She'va, Israel
13Bellinson, Hod Ha-Sharon, None, Israel
14Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel
15hematology, Carmel Medical Center, Haifa, Israel
16Hematology Unit, Bnai Zion Medical Center, Haifa, Israel
17hematology, 12Barzilai Medical Center, Ashkelon, Israel
18Hematology Department, Meir Medical Center, Kfar Saba, Israel
19HaEmek Medical Center, Afula, Israel
20Hematology, Kaplan Medical Center,affiliated with Hadassah and Hebrew University Medical School, Rehovot, Israel
21Assuta University Hospital, Faculty of Health Science, Ben-Gurion University of the Negev, Beersheba, Israel
22Institute of Hematology/Clinic of Histiocytic Neoplasms, Assuta Medical Centers, Tel-Aviv, Israel
23hematology, Rebecca Sieff Hospital, Zefat, Israel
24Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

2:30 PM

Terri L. Parker, MD1, Adam Rosenthal, MS2*, Vaishali Sanchorawala, MD3, Heather J Landau, MD4, Erica Campagnaro, MD5*, Prashant Kapoor, MD6, Natalia Neparidze, MD1, Patrick Hagen, MD7, Shayna Sarosiek, MD8, Emma C. Scott, MD9, Antje Hoering, PhD10, Brian G.M. Durie, MD11, Saad Z. Usmani, MD, MBBS, MBA12 and Robert Z. Orlowski, MD, PhD13

1Section of Hematology, Smilow Cancer Hospital, Yale University School of Medicine, New Haven, CT
2Cancer Research and Biostatistics, Seattle, WA
3Section of Hematology and Oncology, Boston Medical Center and Boston University School of Medicine, Boston, MA
4Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, Scarsdale, NY
5University Hospitals Case Medical Center, Ann Arbor, MI
6Mayo Clinic Rochester, Division of Hematology, Rochester, MN
7Loyola University Medical Center, Maywood, IL
8Boston University Medical Center, Boston, MA
9Knight Cancer Institute, Oregon Health & Science University, Portland, OR
10Seattle Cancer Research and Biostatistics, Seattle, WA
11Cedars Sinai Cancer Center, Los Angeles, CA
12Levine Cancer Institute, Charlotte, NC
13Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX

2:45 PM

Jack Khouri, MD1, Faiz Anwer, MD2, Christy J. Samaras, DO2, Alex V. Mejia Garcia, MD1, Omer N. Koc, MD3, Beth M. Faiman, PhD, CNP2, Kimberly Hamilton, CNP2*, Saveta Mathur, CNP2*, Cynthia Scott, CNP2*, Kathleen Stefunek, RN2*, Josephine Sgobbo, RN2*, Sherry Fada2*, Brittany Lewis2*, Kelly Shepherd2*, Naqib Ahmad2*, Madeleine Knebusch2*, Susan B. Sobolov, PhD4*, Janet Jobes4*, Eileen Daniel4*, Michael Spector, BS4* and Jason Valent, MD2

1Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
2Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Caelum Biosciences, Bordentown, NJ

*signifies non-member of ASH